薬物動態サービス市場：タイプ別、サービスタイプ別、エンドユーザー別-2025-2030年の世界予測

薬物動態サービス市場は、2024年に11億9,000万米ドルと評価され、2025年には13億米ドル、CAGR 9.03%で成長し、2030年には20億1,000万米ドルに達すると予測されています。

薬物動態サービス市場は、新たな技術、複雑な医薬品開発の課題、効率的な治療ソリューションに対する世界の需要の高まりに後押しされ、大きな進化を遂げようとしています。薬物の吸収、分布、代謝、排泄を正確に測定することが最重要視される情勢下、業界関係者は新たな機会を活用し、新たな障害に対処するために戦略を練り直しています。最近の分析法の進歩や新規治療薬の出現により、臨床研究や規制遵守における機敏なアプローチも必要とされています。

薬物動態学サービスは、投与レジメンを最適化し、患者の安全性を高めるための正確なデータ収集とタイムリーな介入戦略を可能にすることで、現在、創薬と開発において重要な役割を果たしています。このダイナミックな分野では、最先端のin-vitroおよびin-vivo試験と高度な計算モデリングを組み合わせた統合サービスの提供が急増しています。組織がこの複雑な地形を乗り切るには、戦略的なイノベーションが不可欠であり、広範な治療領域で確かな成果と競争上の差別化を確保する必要があります。

洗練された機器とデジタル分析の導入は、薬物動態学の戦略的重要性をさらに高め、製薬・バイオテクノロジー業界において不可欠な要素となっています。そのため、利害関係者は、薬剤評価のスピードと精度を向上させるだけでなく、進化する世界の規制基準への準拠を維持するため、研究開発イニシアチブに多額の投資を行っています。現在の市場力学は、最先端技術への投資と共同研究の機会を求めることが、この分野の持続的成長と成功の中心となることを示唆しています。

薬物動態学の情勢を形成する変革的変化

薬物動態サービスの分野では、急速な技術の進歩と進化する顧客の要求によって、変革的なシフトが起きています。近年、自動化システムとデジタル・データ・プラットフォームの広範な統合により、従来の業務が再定義され、医薬品評価に対するより総合的なアプローチが可能になりました。革新的なテクノロジーへの投資により、手作業によるミスが最小限に抑えられ、再現性が向上し、現代の規制の枠組みの厳しい要求を満たすリアルタイムのデータ解析が可能になりました。

さらに、バイオ医薬品の技術革新と高度なアナリティクスの融合は、個別化医療への転換をもたらしました。この転換は単に技術的な導入にとどまらず、多様な患者集団における薬物動態の理解を微調整するという、より広範な戦略的努力を反映しています。業界が適応するにつれて、in-vitroとin-vivoの方法論を融合させるソリューションの重要性が高まり、臨床結果を最適化するための様々な調査モデルの統合が切望されています。

この急激な変革期は、最大限の安全性と有効性を確保しつつ、医薬品開発のライフサイクルを加速させるという点にも焦点が当てられています。新しい研究プロトコールは、強化されたシミュレーションプラットフォームと相まって、研究者がかつてない精度で薬物の挙動を予測することを可能にしています。このような開発により、研究機関、テクノロジーパートナー、規制機関の間で機能横断的な協力が促進され、最終的にはデータ主導のイノベーションが創薬と治療開発の状況を一変させる環境が醸成されています。

市場セグメンテーションによる洞察で市場の成長を狙う

入念なセグメンテーション分析により、薬物動態サービス市場の異質な性質が明確になり、成長が見込まれる分野が明らかになります。市場分析は主に、タイプ、サービスタイプ、エンドユーザー属性に基づいて分類されます。タイプ別に分類すると、市場は伝統的に高分子薬物動態サービスと低分子薬物動態サービスに分かれています。多くの場合、生物製剤や治療用タンパク質のような高分子は、その複雑な構造のため、薬物動態評価において高度に専門的な取り扱いが要求される一方、低分子は、反復的な方法論の強化から恩恵を受け続ける古典的な分析課題をもたらします。

さらに、サービスタイプ別のセグメンテーションでは、in-vitro試験とin-vivo試験という業界の二重の焦点が浮き彫りになっています。in-vitroのセグメントは、初期段階の薬剤評価のために制御された条件を提供する実験室ベースの実験であり、時間効率と費用対効果の高い洞察を提供します。一方、in-vivo試験は、生きた被験者の薬物挙動を評価することで、治療薬の包括的な薬物動態プロファイルを理解するために不可欠な実世界の視点をもたらします。この2種類のサービスを提供できることで、市場開拓企業は医薬品開発のライフサイクル全体に対応するソリューション一式を提供することができます。

さらにエンドユーザー別にセグメント化すると、需要側の多様性と複雑性が浮き彫りになります。市場には、学術・政府研究機関からバイオテクノロジー企業、医薬品開発業務受託機関、大規模製薬企業まで、幅広い顧客が存在します。各分野にはそれぞれ独自の課題や要件があり、調査やサービス提供にはそれぞれに合わせたアプローチが必要となります。技術イノベーター、学術機関、営利企業は、規制と市場の両方の期待に応える調査に注力するため、研究戦略の連携を強めています。この多面的なセグメンテーションフレームワークにより、サービスプロバイダーはリソースの割り当てを最適化し、調査手法を調整し、最終的には顧客のニーズと市場提供の間のより良い調整を達成することができます。このセグメンテーションから引き出される戦略的洞察は、新興国市場の動向や顧客の要望と、製品開発や市場開拓の戦略を一致させるのに役立ちます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の発生率の上昇により薬物動態サービスの利用が拡大
    • 生物製剤とバイオシミラーの成長が薬物動態研究の応用を強化
    • 医薬品研究開発費の大幅な増加により薬物動態評価の重要性が高まっている
  • 抑制要因
    • 薬物動態サービスに影響を与える薬物プロファイルに関連する複雑さ
  • 機会
    • 薬物動態研究の精度と効率を高めるための人工知能の統合
    • 個別化医療の人気の高まりにより薬物動態サービス市場が拡大
  • 課題
    • 頻繁な改正と地域差を伴う複雑な規制環境
• 市場セグメンテーション分析
  • タイプ：個別化医療の需要の高まりが高分子の薬物動態サービスを押し上げる
  • エンドユーザー：製薬企業およびバイオテクノロジー企業からの投資の増加が薬物動態サービスを推進
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 薬物動態サービス市場：タイプ別

• 巨大分子薬物動態サービス
• 小分子薬物動態サービス

第7章 薬物動態サービス市場：サービスタイプ別

• 体外
• 生体内

第8章 薬物動態サービス市場：エンドユーザー別

• 学術機関および政府調査機関
• バイオテクノロジー企業
• 契約調査機関
• 製薬会社

第9章 南北アメリカの薬物動態サービス市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の薬物動態サービス市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの薬物動態サービス市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Absorption Systems LLC
• Allucent
• Aurigene Pharmaceutical Services Ltd.
• Certara
• Charles River Laboratories, Inc.
• Creative Bioarray
• Eurofins Scientific SE
• Evotec SE
• Frontage Laboratories, Inc.
• ICON PLC
• Laboratory Corporation of America Holdings
• LGC Limited by Cinven
• NUVISAN Pharma Holding GmbH
• Pacific BioLabs
• Parexel International（MA）Corporation
• Pfizer Inc.
• PPD Inc. by Thermo Fisher Scientific Inc.
• Premier Consulting
• Reaction Biology Corporation
• SGS SA
• Svar Life Science AB
• WuXi AppTec Co., Ltd.
• XenoTech by BioIVT
• Xyzagen

LIST OF FIGURES

• FIGURE 1. PHARMACOKINETICS SERVICES MARKET MULTI-CURRENCY
• FIGURE 2. PHARMACOKINETICS SERVICES MARKET MULTI-LANGUAGE
• FIGURE 3. PHARMACOKINETICS SERVICES MARKET RESEARCH PROCESS
• FIGURE 4. PHARMACOKINETICS SERVICES MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 15. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 17. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. PHARMACOKINETICS SERVICES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 23. PHARMACOKINETICS SERVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. PHARMACOKINETICS SERVICES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PHARMACOKINETICS SERVICES MARKET DYNAMICS
• TABLE 7. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. POLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. QATAR PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. PHARMACOKINETICS SERVICES MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 146. PHARMACOKINETICS SERVICES MARKET, FPNV POSITIONING MATRIX, 2024

The Pharmacokinetics Services Market was valued at USD 1.19 billion in 2024 and is projected to grow to USD 1.30 billion in 2025, with a CAGR of 9.03%, reaching USD 2.01 billion by 2030.

The pharmacokinetics services market is on the cusp of significant evolution, driven by emerging technologies, complex drug development challenges, and an ever-growing global demand for efficient therapeutic solutions. In a landscape where the accurate measurement of drug absorption, distribution, metabolism, and excretion is paramount, industry stakeholders are refining their strategies to harness new opportunities and address emerging impediments. Recent advancements in analytical methods and the advent of novel therapeutic agents have also necessitated an agile approach in clinical research and regulatory compliance.

Pharmacokinetics services now play a critical role in drug discovery and development by enabling precise data collection and timely intervention strategies that optimize dosing regimens and enhance patient safety. This dynamic field has witnessed a surge in integrated service offerings that combine state-of-the-art in-vitro and in-vivo studies with advanced computational modeling. As organizations navigate this complex terrain, strategic innovation remains a vital ingredient ensuring both robust results and competitive differentiation across a broad spectrum of therapeutic areas.

The introduction of sophisticated instrumentation and digital analytics has further elevated the strategic importance of pharmacokinetics, making it an indispensable facet within the pharmaceutical and biotech industries. Stakeholders are, therefore, investing considerably in research and development initiatives to not only improve the speed and accuracy of drug assessment but also to maintain compliance with evolving global regulatory standards. The current market dynamics signal that investing in cutting-edge technologies and seeking collaborative opportunities will be central to the sustained growth and success of the sector.

Transformative Shifts Reshaping the Pharmacokinetics Landscape

The pharmacokinetics services arena is experiencing transformative shifts powered by rapid technological advancements and evolving customer demands. Over recent years, the widespread integration of automated systems and digital data platforms has redefined traditional practices and enabled a more holistic approach to drug evaluation. Investment in innovative technology has minimized manual errors, enhanced reproducibility, and allowed for real-time data analysis that meets the stringent demands of modern regulatory frameworks.

Furthermore, the convergence of biopharmaceutical innovation and advanced analytics has led to a transformative pivot towards personalized medicine. This shift is not merely about technological adoption but also reflects a broader strategic effort to fine-tune the understanding of drug dynamics in diverse patient populations. As the industry adapts, solutions that merge in-vitro and in-vivo methodologies are assuming greater significance, driving a much-needed integration of various study models to optimize clinical outcomes.

This period of radical transformation is also marked by a keen focus on accelerating the drug development life cycle while ensuring maximum safety and efficacy. New investigative protocols, coupled with enhanced simulation platforms, are allowing researchers to predict drug behavior with unprecedented accuracy. Such developments have encouraged cross-functional collaborations among research institutions, technology partners, and regulatory agencies, ultimately fostering an environment in which innovation driven by data is transforming the landscape of drug discovery and therapeutic development.

Key Segmentation Insights for Targeted Market Growth

A careful segmentation analysis provides a clear view of the heterogeneous nature of the pharmacokinetics services market, illuminating the areas that are primed for growth. The market analysis is primarily categorized based on type, service type, and end-user demographics. When examining the segmentation based on type, the market has been traditionally divided between offerings for large molecules pharmacokinetics services and small molecules pharmacokinetics services. In many cases, large molecules, such as biologics and therapeutic proteins, demand highly specialized handling during pharmacokinetic assessment due to their complex structure, while small molecules bring forward classic analytical challenges that continue to benefit from iterative methodological enhancements.

In addition, segmentation in terms of service type highlights the dual focus of the industry around in-vitro and in-vivo studies. The in-vitro segment represents laboratory-based experiments that provide controlled conditions for early-stage drug evaluation, offering time-efficient and cost-effective insights. Conversely, in-vivo studies bring an essential real-world perspective to the table by evaluating drug behavior in live subjects, which is indispensable for understanding the comprehensive pharmacokinetic profile of therapeutic agents. The ability to provide both types of services allows market players to offer a complete suite of solutions that cater to the complete lifecycle of drug development.

Further segmentation by end-user underscores the diversity and complexity of the demand side. The market landscape encompasses a wide array of clients ranging from academic and government research institutes to biotechnology companies, contract research organizations, and large-scale pharmaceutical companies. Each segment brings its unique challenges and requirements, necessitating a tailored approach to research and service delivery. Technology innovators, academic institutions, and commercial players are increasingly aligning their research strategies to focus on delivers that meet both regulatory and market expectations. This multifaceted segmentation framework enables service providers to optimize resource allocation, tailor their research methodologies, and ultimately achieve better alignment between client needs and market offerings. The strategic insights drawn from this segmentation are instrumental in aligning product development and marketing strategies with emerging trends and client demands.

Based on Type, market is studied across Large Molecules Pharmacokinetics Services and Small Molecules Pharmacokinetics Services.

Based on Service Type, market is studied across In-Vitro and In-Vivo.

Based on End-User, market is studied across Academic & Government Research Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies.

Emerging Regional Trends Shaping Market Dynamics

The pharmacokinetics services market is hugely influenced by regional trends that dictate regulatory frameworks, innovation capacities, and overall market dynamics. In the Americas, robust infrastructure and a highly developed network of research institutions foster a conducive environment for advanced pharmacokinetic investigations. This region benefits from well-established partnerships between academic and commercial entities, ensuring that the industry remains at the forefront of scientific breakthroughs and regulatory compliance.

Meanwhile, the combined region of Europe, Middle East, and Africa exhibits a diversified landscape where traditional research ecosystems meet emerging technological hubs. The interplay of different regulatory bodies within Europe and the growing innovation pockets in the Middle East and Africa have led to a flexible yet highly competitive environment. The region's diverse market conditions, varying from stringent regulatory oversight in Europe to more agile exploratory approaches in other parts, require service providers to adopt adaptable strategies that balance caution with innovation.

In Asia-Pacific, rapid economic growth combined with strong governmental support for pharmaceutical research has cemented the region's position as a key player in the global pharmacokinetics market. The emphasis on research and development, significant investments in biotechnology, and a surge in academic outputs have stimulated the demand for specialized pharmacokinetic services. The region benefits from a burgeoning talent pool and increased focus on integrating novel methodologies with traditional practices, setting the stage for accelerated market growth over the coming years. Overall, these regional insights point towards the need for global companies to adapt their strategies to cater to varying regional requirements while leveraging emerging trends for sustainable market expansion.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Leading Companies Driving Market Innovation

An analysis of the key companies active in the pharmacokinetics space reveals a competitive landscape where leaders are continuously pushing the boundaries of scientific innovation and service quality. Industry frontrunners include prominent firms such as Absorption Systems LLC and Allucent, which have built their reputations on delivering robust analytic methodologies that streamline early drug development phases. Other innovators like Aurigene Pharmaceutical Services Ltd. and Certara have become synonymous with excellence in both in-vitro and in-vivo studies, offering comprehensive solutions that address the intricate challenges of modern pharmacokinetics.

Major players such as Charles River Laboratories, Inc. and Creative Bioarray harness advanced technological platforms to deliver precise pharmacokinetic measurements and robust data analytics. The contributions of Eurofins Scientific SE and Evotec SE have redefined industry benchmarks with their combination of expertise and innovative research paradigms. Frontage Laboratories, Inc., ICON PLC, and Laboratory Corporation of America Holdings are further notable examples, consistently pushing the envelope in integrating research methods, streamlining processes, and ensuring regulatory adherence.

The market also sees significant contributions from industry leaders including LGC Limited by Cinven, NUVISAN Pharma Holding GmbH, Pacific BioLabs, Parexel International (MA) Corporation, and Pfizer Inc., whose strategic initiatives are aligned with advancing the drug development life cycle. Additional noteworthy players such as PPD Inc. by Thermo Fisher Scientific Inc., Premier Consulting, Reaction Biology Corporation, SGS SA, Svar Life Science AB, WuXi AppTec Co., Ltd., XenoTech by BioIVT, and Xyzagen collectively drive the competitive intensity and innovation within the pharmacokinetics services market. Their combined efforts in fostering collaboration, investing in new technologies, and streamlining study protocols set the stage for future advancements in drug development and tailored therapeutic strategies.

The report delves into recent significant developments in the Pharmacokinetics Services Market, highlighting leading vendors and their innovative profiles. These include Absorption Systems LLC, Allucent, Aurigene Pharmaceutical Services Ltd., Certara, Charles River Laboratories, Inc., Creative Bioarray, Eurofins Scientific SE, Evotec SE, Frontage Laboratories, Inc., ICON PLC, Laboratory Corporation of America Holdings, LGC Limited by Cinven, NUVISAN Pharma Holding GmbH, Pacific BioLabs, Parexel International (MA) Corporation, Pfizer Inc., PPD Inc. by Thermo Fisher Scientific Inc., Premier Consulting, Reaction Biology Corporation, SGS SA, Svar Life Science AB, WuXi AppTec Co., Ltd., XenoTech by BioIVT, and Xyzagen. Actionable Recommendations for Industry Leaders

Industry leaders must adopt strategic initiatives to maintain a competitive edge in the rapidly evolving pharmacokinetics landscape. First and foremost, investing in novel technological platforms is imperative for increasing both the speed and accuracy of drug evaluation. Leaders should explore opportunities to integrate artificial intelligence and machine learning into data analysis processes, which could streamline study designs and improve predictive outcomes in both in-vitro and in-vivo environments.

Additionally, fostering collaborative partnerships with academic institutions, regulatory agencies, and technology innovators will help bridge the gap between traditional pharmacokinetic methods and emerging trends. Such collaborations should aim at mutual knowledge exchange and co-development of tailored solutions that align with the evolving demands of drug safety and efficacy assessments. Industry players are encouraged to build robust, customizable platforms that can cater to unique client requirements, whether those are driven by the demands of large molecules or small molecules studies.

Adaptability is another crucial factor. Markets are increasingly segmented along various lines, including type, service delivery, and end-user profiles. Leaders must thus ensure that their service portfolios are sufficiently diverse to cater to academic, pharmaceutical, biotechnology, and contract research clients. By aligning service offerings with specific needs and embracing a modular approach to research capabilities, companies can better navigate regulatory changes and shifting market dynamics.

Moreover, advancing training programs and continuous education initiatives will be key to building a workforce prepared to tackle complex research challenges. Emphasizing skill development in emerging analytical techniques and cross-disciplinary methodologies can significantly enhance the quality of study outcomes. In conclusion, a forward-thinking approach that combines investment, collaboration, and meticulous resource management is essential for sustaining long-term growth and operational excellence in the pharmacokinetics services market.

Conclusion: Charting the Future of Pharmacokinetics Services

The evolving dynamics of the pharmacokinetics services market present both significant challenges and exciting opportunities. As the industry continues to integrate innovative technologies and adapt to diverse regional and client segmentation dynamics, the focus on delivering high-quality, compliant, and cost-effective study solutions remains paramount. The combined emphasis on technological advancement, strategic partnerships, and market-specific adaptations is laying a firm foundation for sustained growth and operational excellence.

This comprehensive market analysis underscores the importance of adopting a multifaceted approach that embraces changes in study design, regulatory landscapes, and digital transformation. By driving innovation, aligning service portfolios with specific client needs, and reinforcing global collaborations, industry stakeholders can set new benchmarks in pharmacokinetics services that support the rapid pace of drug discovery and therapeutic innovation. The future is bright for organizations that are prepared to invest in advanced methodologies and adapt dynamically to the constantly shifting market realities.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence of chronic diseases prompting expanded pharmacokinetic service utilization
    • 5.1.1.2. Growth in biologics and biosimilars fueling enhanced application of pharmacokinetic studies
    • 5.1.1.3. Significant growth in pharmaceutical R&D expenditure elevating the importance of pharmacokinetics assessments
  • 5.1.2. Restraints
    • 5.1.2.1. Complexities associated with drug profiles impacting pharmacokinetics services
  • 5.1.3. Opportunities
    • 5.1.3.1. Integration of artificial intelligence for enhancing accuracy and efficiency of pharmacokinetics studies
    • 5.1.3.2. Increasing popularity of personalized medicine expanding market of pharmacokinetics service
  • 5.1.4. Challenges
    • 5.1.4.1. Complex regulatory landscapes with frequent amendments and regional differences
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Rising demand for personalized medicine boosts the pharmacokinetics services for large molecules
  • 5.2.2. End-User: Increasing investments from pharmaceutical & biotechnology companies driving pharmacokinetics services
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Pharmacokinetics Services Market, by Type

• 6.1. Introduction
• 6.2. Large Molecules Pharmacokinetics Services
• 6.3. Small Molecules Pharmacokinetics Services

7. Pharmacokinetics Services Market, by Service Type

• 7.1. Introduction
• 7.2. In-Vitro
• 7.3. In-Vivo

8. Pharmacokinetics Services Market, by End-User

• 8.1. Introduction
• 8.2. Academic & Government Research Institutes
• 8.3. Biotechnology Companies
• 8.4. Contract Research Organizations
• 8.5. Pharmaceutical Companies

9. Americas Pharmacokinetics Services Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Pharmacokinetics Services Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Pharmacokinetics Services Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. FPNV Positioning Matrix, 2024
• 12.3. Competitive Scenario Analysis
  • 12.3.1. TC BioPharm and CareDx collaborate for enhanced monitoring in cell therapy clinical trial
  • 12.3.2. Sai Life Sciences enhances DMPK capabilities for large-scale collaborations
  • 12.3.3. Frontage Laboratories strengthens European market presence with Accelera acquisition
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Absorption Systems LLC
• 2. Allucent
• 3. Aurigene Pharmaceutical Services Ltd.
• 4. Certara
• 5. Charles River Laboratories, Inc.
• 6. Creative Bioarray
• 7. Eurofins Scientific SE
• 8. Evotec SE
• 9. Frontage Laboratories, Inc.
• 10. ICON PLC
• 11. Laboratory Corporation of America Holdings
• 12. LGC Limited by Cinven
• 13. NUVISAN Pharma Holding GmbH
• 14. Pacific BioLabs
• 15. Parexel International (MA) Corporation
• 16. Pfizer Inc.
• 17. PPD Inc. by Thermo Fisher Scientific Inc.
• 18. Premier Consulting
• 19. Reaction Biology Corporation
• 20. SGS SA
• 21. Svar Life Science AB
• 22. WuXi AppTec Co., Ltd.
• 23. XenoTech by BioIVT
• 24. Xyzagen